Related Experiment Video
Updated: May 15, 2026
09:36
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
CROI 2026: Acute and Postacute COVID-19
1Johns Hopkins University, Baltimore, MD, USA.
Topics in Antiviral Medicine
|May 13, 2026
Summary
Advances in COVID-19 research include new DNA-encoded monoclonal antibody (DMAb) technology and insights into long COVID. Studies show continued SARS-CoV-2 risks and patient experiences, highlighting the need for better understanding and care.
Area of Science:
- Infectious Diseases
- Immunology
- Virology
Background:
- The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted key advancements in understanding COVID-19 and related conditions.
- Research explored viral immunity, therapeutics, and the long-term impacts of SARS-CoV-2 infection.
Purpose of the Study:
- To summarize critical findings presented at CROI 2026 concerning COVID-19, long COVID, and HIV co-infections.
- To evaluate novel therapeutic platforms and assess the ongoing risks and sequelae of SARS-CoV-2 infection.
Main Methods:
- First-in-human validation of DNA-encoded monoclonal antibody (DMAb) technology.
- Clinical studies on pemivibart in advanced HIV patients.
- Pharmacokinetic and safety studies of a novel pan-coronavirus protease inhibitor.
- Observational studies on SARS-CoV-2 infection outcomes and long COVID prevalence.
Main Results:
- DMAb technology demonstrated safety and durable antibody production.
- Pemivibart was well-tolerated in advanced HIV, inducing neutralizing antibodies.
- A new protease inhibitor showed comparable safety and pharmacokinetics in renal and hepatic impairment.
- Post-SARS-CoV-2 infection carries risks for new diagnoses and comorbidity worsening; HIV co-infection impacts renal function.
- No association found between circulating SARS-CoV-2 antigen and long COVID; patients report clinical stigma.
Conclusions:
- Novel DMAb technology shows promise for therapeutic antibody development.
- New antiviral agents offer potential treatment options with favorable safety profiles.
- Long-term health consequences of SARS-CoV-2 infection, particularly in vulnerable populations like people with HIV, require continued monitoring.
- Patient-reported experiences highlight significant psychosocial challenges associated with long COVID.
Related Concept Videos
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:21Acute Respiratory Failure-I
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:30Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
01:30Acute Pharyngitis
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause: